Outcome for triple negative breast cancer in a retrospective cohort with an emphasis on response to platinum-based neoadjuvant therapy

PURPOSE: The rate of pathological complete response (pCR) for patients with triple negative breast cancer (TNBC) is increased when carboplatin is added to neo-adjuvant chemotherapy (NACT). However, while phase III trial data showing a survival benefit are awaited, carboplatin is not yet standard-of-...

Descripción completa

Detalles Bibliográficos
Autores principales: Walsh, Elaine M., Shalaby, Aliaa, O’Loughlin, Mark, Keane, Nessa, Webber, Mark J, Kerin, Michael J., Keane, Maccon M., Glynn, Sharon A., Callagy, Grace M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2018
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6418073/
https://www.ncbi.nlm.nih.gov/pubmed/30488345
http://dx.doi.org/10.1007/s10549-018-5066-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6418073/
https://www.ncbi.nlm.nih.gov/pubmed/30488345
http://dx.doi.org/10.1007/s10549-018-5066-6

Ejemplares similares